What does a DHEA‑S level of 37 µg/dL indicate and what management steps are recommended?

DHEA-S Level of 37 µg/dL: Clinical Significance and Management

A DHEA-S level of 37 µg/dL is markedly low and requires immediate evaluation for adrenal insufficiency, particularly in women, where this value falls well below normal ranges and strongly suggests hypothalamic-pituitary-adrenal (HPA) axis dysfunction.

Clinical Interpretation

What This Level Indicates

A DHEA-S of 37 µg/dL represents significant adrenal androgen deficiency. The clinical significance depends critically on patient sex and age:

In Women:

• This level is severely suppressed and highly concerning for adrenal insufficiency 1
• DHEA-S below 40 µg/dL diagnoses autonomous cortisol secretion (paradoxically indicating adrenal dysfunction) with 84% specificity and 81% positive predictive value 2
• In the context of suspected adrenal insufficiency, very low age- and gender-matched DHEA-S levels make the diagnosis extremely likely 3
• A normal age- and gender-specific DHEA-S level makes corticotropin deficiency extremely unlikely; conversely, a low level mandates further HPA axis testing 3

In Men:

• DHEA-S below 55.4 µg/dL (15th percentile) is associated with increased heart failure hospitalization (HR 1.30) and mortality risk 4
• Below 70.0 µg/dL (25th percentile) carries increased death risk (HR 1.12) 4

Differential Diagnosis Priority

Immediate considerations:

1. Primary or secondary adrenal insufficiency - Most critical diagnosis to exclude
2. Functional hypothalamic amenorrhea (FHA) - In women with menstrual irregularities 5
3. Glucocorticoid-induced adrenal insufficiency - If any glucocorticoid exposure history 6
4. Hypopituitarism - Particularly with pituitary adenomas or immune checkpoint inhibitor therapy 7

Immediate Diagnostic Workup

Essential First-Line Tests (Perform Within 24-48 Hours)

Morning (8 AM) blood draw:

• Serum cortisol - If <150 nmol/L (5 µg/dL), adrenal insufficiency is highly likely 6
• ACTH - Distinguishes primary (elevated ACTH) from secondary (low/normal ACTH) adrenal insufficiency 5
• Electrolytes - Hyponatremia and hyperkalemia suggest primary adrenal insufficiency 7

Additional hormonal assessment:

• TSH and free T4 - Central hypothyroidism often coexists with secondary adrenal insufficiency 7
• LH, FSH, testosterone (males) or estradiol (premenopausal females) - Assess for panhypopituitarism 7

Dynamic Testing Considerations

Do NOT routinely perform dynamic testing initially 6. However, if morning cortisol is 150-300 nmol/L (5-10 µg/dL), consider:

• Standard-dose ACTH stimulation test (250 µg) - Gold standard for confirming adrenal insufficiency 1
• Peak cortisol <500 nmol/L (18 µg/dL) confirms diagnosis 1

Critical caveat: In acute presentations with morning cortisol <150 nmol/L (5 µg/dL), do not delay treatment for dynamic testing - initiate glucocorticoid replacement immediately 6.

Management Algorithm

If Adrenal Insufficiency is Confirmed or Highly Suspected

Immediate actions:

1. Initiate glucocorticoid replacement FIRST (before any other hormone replacement to avoid precipitating adrenal crisis) 7:

   • Hydrocortisone 15-20 mg daily in divided doses (typically 10 mg morning, 5 mg afternoon) 1, 7
   • Alternative: Prednisone 5 mg daily 7

2. Assess for mineralocorticoid deficiency (primary adrenal insufficiency only):

   • If ACTH elevated and electrolyte abnormalities present, add fludrocortisone 0.05-0.1 mg daily 1

3. Provide emergency education immediately 1, 7:

   • Stress dosing protocols (double or triple dose during illness)
   • Emergency injectable hydrocortisone prescription
   • Medical alert bracelet/necklace
   • Written instructions for adrenal crisis recognition

4. Endocrinology referral within 1-2 weeks 7

If Adrenal Function is Borderline or Uncertain

For morning cortisol 150-300 nmol/L (5-10 µg/dL):

• Continue physiologic glucocorticoid replacement
• Recheck morning cortisol every few weeks until recovery or confirmation of insufficiency 6
• Consider ACTH stimulation testing if levels remain indeterminate 6

Cortisol >300 nmol/L (10 µg/dL) suggests HPA axis recovery - can consider tapering replacement under close monitoring 6

Special Consideration: DHEA Replacement in Women

For women with confirmed adrenal insufficiency and persistent symptoms despite optimized glucocorticoid/mineralocorticoid replacement 1:

• Consider DHEA 25-50 mg oral daily if experiencing:

  • Low libido
  • Depressive symptoms
  • Low energy levels

• Monitor with morning DHEA-S levels (before daily dose), targeting mid-normal premenopausal range 1

• Trial period: 6 months - discontinue if no sustained benefit 1

Important limitation: Evidence for routine DHEA replacement is insufficient; systematic reviews show no substantial clinical benefit in most patients 1

Context-Specific Scenarios

In Hyperandrogenism Evaluation

If evaluating for PCOS or hyperandrogenism, a DHEA-S of 37 µg/dL is inconsistent with adrenal androgen excess 5, 8:

• DHEA-S >600 µg/dL suggests adrenal tumor 5
• This low level redirects focus toward ovarian sources or adrenal insufficiency masking hyperandrogenism

In Functional Hypothalamic Amenorrhea

Low DHEA-S is expected in FHA due to suppressed HPA axis 5. However, must still exclude primary adrenal pathology with morning cortisol and ACTH.

Post-Glucocorticoid Therapy

If recent glucocorticoid exposure (any formulation - oral, inhaled, topical, intra-articular) 6:

• Low DHEA-S indicates prolonged HPA suppression
• Recovery of cortisol secretion typically precedes DHEA-S normalization 6
• Continue replacement until morning cortisol consistently >300 nmol/L (10 µg/dL) 6

Critical Pitfalls to Avoid

1. Never start thyroid hormone replacement before glucocorticoid replacement - accelerates cortisol clearance and can precipitate adrenal crisis 7

2. Do not rely on DHEA-S alone for diagnosis - always confirm with cortisol and ACTH 3

3. Recognize assay variability - familiarize yourself with your laboratory's reference ranges and methodology 6

4. Do not overlook non-oral glucocorticoid exposure - inhaled, topical, and intra-articular formulations can cause adrenal suppression 6

5. In elderly patients, distinguish between physiologic age-related DHEA-S decline versus pathologic suppression - use age-adjusted reference ranges 1, 4

Follow-Up Monitoring

If on replacement therapy:

• Morning cortisol every 1-6 months (depending on dose and clinical trajectory) 6
• DHEA-S monitoring only if on DHEA replacement 1
• Clinical assessment for signs of over-replacement (weight gain, hypertension, hyperglycemia) or under-replacement (fatigue, hypotension) 1

Goal: Maintain cortisol in physiologic range while allowing HPA axis recovery if glucocorticoid-induced 6